Biosimilar switch for fabry disease shows promise in small trial
NCT ID NCT05843916
First seen Feb 25, 2026 · Last updated May 22, 2026 · Updated 14 times
Summary
This study tested whether a new, similar version of the drug agalsidase beta (called AGA BETA BS) works as well as the standard drug Fabrazyme in people with Fabry disease. Twenty adults who were already stable on Fabrazyme switched to the new drug for 6 months to a year. The main goal was to check if a key disease marker in the blood stayed the same, showing the new drug is equally effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FABRY DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centro Médico Santa María de la Salud
San Isidro, Buenos Aires, 1642, Argentina
-
Centro Oncológico Riojano Integral
La Rioja, F5300, Argentina
-
Clínica Universitaria Reina Fabiola
Córdoba, X5004, Argentina
-
Instituto de Investigaciones Clínicas Quilmes
Buenos Aires, Argentina
-
Instituto de Nefrología Pergamino S.R.L
Pergamino, Buenos Aires, 2700, Argentina
Conditions
Explore the condition pages connected to this study.